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Abstract 
Tumor necrosis factor (TNF) is a major cytokine in the pathogenesis of inflammatory bowel 
disease (IBD), and TNF inhibition is a cornerstone of contemporary IBD therapy. However, 
paradoxical induction of IBD has recently been reported upon treatment of rheumatologic 
disorders with TNF inhibitors. In previous cases, induction of IBD was associated with one 
single drug and IBD was successfully managed by switching TNF inhibitors. We report the 
case of a patient with juvenile rheumatoid arthritis under long-term treatment with etaner-
cept. After switching TNF inhibition to adalimumab, symptoms of Crohn’s disease (CD) oc-
curred and the diagnosis of CD was established by endoscopy. Further treatment with ada-
limumab and subsequently infliximab aggravated the abdominal symptoms, necessitating 
ileocecal resection, after which symptoms resolved for several months. Etanercept treatment 
due to recurrent rheumatologic symptoms was followed by recurrent CD symptoms and 
findings, which resolved upon discontinuation of etanercept. This case suggests that induc-
tion, aggravation and recurrence of IBD can be rare class effects of TNF inhibition. 
© 2015 S. Karger AG, Basel 
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Introduction 
Tumor necrosis factor (TNF) plays a central role in the pathogenesis of inflammatory 
bowel disease (IBD), and the introduction of TNF inhibitors has substantially broadened the 
therapeutic options in IBD [1]. Available monoclonal antibodies which are effective for the 
treatment of Crohn’s disease (CD) and ulcerative colitis include infliximab and adalimumab 
[2]. In contrast etanercept, a fusion protein of the human soluble TNF receptor p75 with the 
Fc fragment of human immunoglobulin G1, was shown to be safe but not effective in CD [3]. 
The reasons for this differential effect of infliximab/adalimumab and etanercept are not 
understood, but might include complement-dependent cytotoxicity and induction of apopto-
sis by infliximab/adalimumab, but not by etanercept. Vice versa, lymphotoxin is bound and 
neutralized by etanercept, but not the antibodies [4]. 
Therapy with TNF inhibitors has an acceptable safety profile and besides infusion reac-
tions, the adverse events of TNF inhibitor treatment are mainly infectious complications, 
including tuberculosis, as might be expected from their mode of action [5]. Paradoxical im-
mune activation by TNF inhibitors has also been described, and autoimmune disorders, in-
cluding psoriasis, vasculitis, systemic lupus erythematosus, interstitial lung disease and sar-
coidosis, have been reported as adverse events of TNF inhibitor treatment [6]. The mecha-
nisms of autoimmune-like syndromes during TNF blockade have not be clarified, but auto-
immune-like syndromes might be caused by cytotoxicity of the drugs, increase of inter-
feron-α levels by TNF, dysregulation of T cells and unrecognized infectious complications. 
Furthermore, direct or indirect effects of TNF inhibitors might induce exposure towards 
autoantigens, including self-DNA or self-RNA, which could act as endogenous ligands of Toll-
like receptors and lead to autoimmunity [7]. 
Paradoxical induction of IBD by the TNF inhibitor etanercept has been described in sem-
inal case reports and systematic analyses [8, 9]. IBD as an adverse event of treatment is not 
limited to etanercept treatment, since recent case series also included cases of IBD induced 
by infliximab or adalimumab [10]. However, in the cases described, new-onset IBD could be 
treated by switching TNF inhibitors, usually to infliximab or adalimumab, and idiosyncratic 
effects of the culprit drugs could not be excluded. We report a case with new onset, progres-
sion and recurrence of CD upon treatment with three different TNF inhibitors, suggesting 
paradoxical induction of IBD as a class effect of TNF inhibitors. 
Case Presentation 
A 19-year-old man presented to our division for the management of severe right lower 
quadrant pain. His previous history was remarkable for juvenile rheumatoid arthritis start-
ing at 12 years of age, involving the sacroiliac and mandibular joint as well as the right ankle 
and hip. He was tested positive for HLA-B27, but tests for antinuclear antibodies and rheu-
matoid factor proved to be negative. At 16 years of age etanercept 50 mg s.c. was started 
which initially relieved the symptoms, so the dose was reduced to every 2 weeks after 1 year 
of treatment. However, 1 year later the joint pain recurred and was refractory to etanercept 
dose escalation (weekly) and add-on naproxen. Two months before the onset of abdominal 
pain the treatment regime was changed to adalimumab 40 mg s.c. every 2 weeks and the 
patient remained free of rheumatologic problems for the next year. 
During evaluation for abdominal pain, lower right quadrant tenderness and a palpable 
tumor were noted. Blood work revealed systemic inflammation (C-reactive protein 46 mg/l 
and leukocytosis with 13.7 × 109 leucocytes per liter with 84% neutrophils). Ultrasound and 
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computed tomography suggested terminal ileitis and abdominal lymphadenopathy. Stool 
tests for microorganisms including Clostridium difficile were negative. Colonoscopy demon-
strated an ulcerated ileocecal valve with a narrow opening that could not be intubated. His-
tology confirmed granulomatous inflammation and acute inflammation, and all tests for in-
fectious diseases, including acid-fast staining, mycobacteria cultures and immunohistochem-
istry for cytomegalovirus, were negative. 
Since the patient’s presentation was consistent with new-onset CD, we continued ada-
limumab treatment and started budesonide at 9 mg/day. Subsequently, abdominal pain im-
proved; however, surveillance of small bowel inflammation by abdominal ultrasound con-
tinued to show wall thickening >6 mm, consistent with active inflammation, and budesonide 
was increased to 15 mg/day. Due to recurrent abdominal symptoms treatment was switched 
to infliximab 5 mg/kg body weight, but abdominal pain only temporarily improved and re-
curred only 3 months after starting infliximab. The patient was now complaining of constant 
abdominal pain and had lost 12 kg of body weight (body mass index 16 kg/m2). Magnetic 
resonance imaging revealed chronic terminal ileitis and a complex fistula system. In hospital 
parenteral nutrition was started, infliximab was stopped, and 9 months after the onset of 
abdominal pain, right-sided colectomy with an ileocolic anastomosis was performed (fig. 1). 
The immediate postoperative course was unremarkable; the patient remained free of symp-
toms and body weight increased. 
Three months after surgery, joint inflammation recurred in the hips, shoulders, right 
foot, lumbar spine and sacroiliac joint. Due to limited therapeutic options for the treatment 
of ileosacral arthritis, etanercept 50 mg s.c. weekly was restarted after careful discussion 
with the patient. Etanercept immediately relived joint pains, but 14 days after restarting the 
TNF inhibitor abdominal pain recurred, accompanied by an increase in calprotectin levels. 
Colonoscopy revealed multiple ulcers at the ileocolic anastomosis and histology confirmed 
ulceration. Abdominal pain slowly resolved after etanercept had been discontinued. The 
clinical course is summarized in figure 2. 
Discussion and Conclusions 
In our patient induction, aggravation and recurrence of CD occurred during treatment 
with three different TNF inhibitors (adalimumab, infliximab and etanercept). According to 
the Naranjo algorithm [11], a consensus algorithm to estimate the probability of causality in 
a suspected drug-induced clinical event, a definite association between TNF inhibitor treat-
ment and CD as an adverse drug event is present in our patient (10 out of 13 possible 
points). Importantly, there has been no alternative explanation of IBD in our patient with a 
negative family history for IBD and only a brief period of naproxen treatment, which had 
been discontinued weeks before the initial onset of abdominal pain. However, some limita-
tions of the Naranjo algorithm exist and some ambiguity remains: Following a recent analy-
sis of new-onset IBD as an adverse event of TNF inhibitor treatment, we did not score juve-
nile idiopathic arthritis as an alternative explanation for IBD in our patient [12]. The possi-
bility of joint involvement as an extraintestinal manifestation of IBD preceding the onset of 
CD for several years seems unlikely but cannot be rigorously excluded. For consistency, the 
Naranjo score was applied as in the previous larger study [12]. 
Proof for an association of IBD with TNF treatment is strongest for etanercept. In addi-
tion to seminal case reports, larger case series have now been published. Thereby, in a re-
port from a European etanercept registry for treatment of juvenile idiopathic arthritis, 13 
cases of new-onset IBD (including 9 cases with CD) were noted. The authors calculated a 
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43-fold increased risk for IBD compared to the control population. Of note, 10 of the patients 
were subsequently treated with another TNF inhibitor (5 each, infliximab and adalimumab) 
[13]. A second case series from France identified 8 patients with juvenile idiopathic arthritis 
and etanercept treatment (5 cases with CD and 3 cases with unclassified colitis). The clinical 
course of all patients was favorable upon discontinuation of etanercept; 6 of 8 patients were 
successfully treated with infliximab [9]. 
Within the last years, infliximab and adalimumab have increasingly been used for the 
treatment of rheumatic disorders and, likely due to increased patient exposure, evidence of 
paradoxical induction of IBD was also observed for these antibodies. A recent French series 
described 16 patients with rheumatoid arthritis and new-onset IBD under TNF inhibitor 
treatment (14 cases with etanercept, 2 with adalimumab). Similarly to the previous series, 
most of the patients had CD (8 and 6 cases with CD and Crohn’s-like disease, respectively, 
and 1 case with unclassified colitis), and all patients could be successfully treated by switch-
ing the TNF inhibitor to infliximab or adalimumab [10]. Finally, a recent publication analyz-
ing all adverse events regarding TNF inhibitors reported to the FDA described 158 cases of 
new-onset IBD. Most of the cases involved etanercept, but 28 cases of infliximab, 24 cases of 
adalimumab and 1 case of golimumab were listed. 111 of the associations were regarded as 
‘possible’ and 47 as ‘probable’ according to the Naranjo algorithm [12]. 
Taken together, the various case reports and case series reporting new-onset IBD upon 
etanercept treatment strongly suggest that etanercept can rarely trigger IBD in susceptible 
patients. Paradoxical induction of IBD by infliximab and adalimumab is also likely, even 
though the evidence is weaker. Therefore, TNF inhibition seems to have paradoxical pro-
inflammatory properties which are usually extinguished by its anti-inflammatory effects. It 
is tempting to speculate that etanercept, which has no proven therapeutic effects against CD, 
can cause overt mucosal inflammation more often than infliximab or adalimumab, which are 
highly effective against IBD. Following this model, only in those few patients for whom the 
inflammatory process is completely resistant to TNF inhibition can inflammation progress to 
clinically overt CD. 
Specific risk factors for the development of paradoxical IBD in patients exposed to 
etanercept or infliximab/adalimumab remain to be elucidated. In addition, it is unknown 
why TNF inhibition would trigger mainly CD or unclassified colitis. In any case, our report 
adds evidence regarding the great variability in the pathways utilized for the inflammatory 
process in different patients and suggests that TNF can be protective in at least a few pa-
tients [14]. 
The management of IBD cases triggered by TNF inhibitors is largely identical to that of 
classical IBD cases, and in addition to discontinuation of the offending drug, standard IBD 
treatment should be applied [15]. When appropriate, switching the TNF inhibitor also seems 
to be safe; however, if symptoms persist or worsen even upon treatment with a second in-
hibitor (as in our patient), alternative treatment options should be pursued. 
In summary, we present the first case of a patient in whom the onset, aggravation and 
recurrence of CD were triggered by TNF inhibition with three different TNF inhibitors, and 
our results point to CD as a rare adverse event and a class effect of TNF inhibitors. 
 
 
110 
 
Case Rep Gastroenterol 2015;9:106–112 
DOI: 10.1159/000381637 
 
© 2015 S. Karger AG, Basel 
www.karger.com/crg 
Zeitz et al.: New Onset, Aggravation and Recurrence of Crohn’s Disease upon 
Treatment with Three Different Tumor Necrosis Factor Inhibitors 
 
 
 
Author Contributions 
B. Misselwitz and J. Zeitz drafted the manuscript. G. Rogler, S. Enderlin, L. Biedermann, 
M. Turina, S. Leibl and M. Prakash edited the manuscript for important intellectual content. 
M. Prakash, B. Misselwitz, M. Turina and S. Leibl prepared the figures. All authors read and 
approved the final version of the manuscript. 
Disclosure Statement 
B. Misselwitz has received travel grants from Vifor and Novartis and speaker’s honorar-
ia from MSD and Tillots. L. Biedermann has received research support from UCB, travel 
grants from MSD, Abbvie and Vifor, and fees for consulting/advisory boards from MSD, 
Abbvie and UCB. G. Rogler has consulted to Abbott, Abbvie, Boehringer, Calypso, FALK, 
Genentech, Essex/MSD, Novartis, Pfizer, Roche, UCB, Takeda (Switzerland), Tillots and Vifor, 
has received speaker’s honoraria from Astra Zeneca, Abbott, Abbvie, FALK, MSD, Phadia, 
Tillots, UCB, and Vifor, and has received educational grants and research grants from Abbot, 
Abbvie, Ardeypharm, Essex/MSD, FALK, Flamentera, Novartis, Roche, Tillots, UCB and Zeller. 
J. Zeitz has received a research grant from Abbvie. S. Leibl, S. Enderlin, M. Turina and M. Pra-
kash have no conflict of interests. 
References 
1 Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122: 
1592–1608. 
2 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P: Efficacy of biological therapies in 
inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644–659; 
quiz 660. 
3 Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, 
Zinsmeister AR: Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. 
Gastroenterology 2001;121:1088–1094. 
4 Marotte H, Cimaz R: Etanercept – TNF receptor and IgG1 Fc fusion protein: is it different from other TNF 
blockers? Expert Opin Biol Ther 2014;14:569–572. 
5 Targownik LE, Bernstein CN: Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J 
Gastroenterol 2013;108:1835–1842; quiz 1843. 
6 Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M, BIOGEAS study group: Biologics-induced autoimmune 
diseases. Curr Opin Rheumatol 2013;25:56–64. 
7 Prinz JC: Autoimmune-like syndromes during TNF blockade: does infection have a role? Nat Rev Rheumatol 
2011;7:429–434. 
8 Wiegering V, Morbach H, Dick A, Girschick HJ: Crohn’s disease during etanercept therapy in juvenile 
idiopathic arthritis: a case report and review of the literature. Rheumatol Int 2010;30:801–804. 
9 Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R, Paraf F, Languepin J, Wouters CH, 
Guillot M, Quartier P, Bader-Meunier B; SOFREMIP: Occurrence of inflammatory bowel disease during 
treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology 
(Oxford) 2010;49:1694–1698. 
10 Toussirot E, Houvenagel E, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, 
Berthelot JM, Bader-Meunier B, Kantelip B; Le CRI: Development of inflammatory bowel disease during 
anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 2012;79: 
457–463. 
11 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method 
for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245. 
12 Krishnan A, Stobaugh DJ, Deepak P: Assessing the likelihood of new-onset inflammatory bowel disease 
following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid 
arthritis. Rheumatol Int 2015;35:661–668. 
111 
 
Case Rep Gastroenterol 2015;9:106–112 
DOI: 10.1159/000381637 
 
© 2015 S. Karger AG, Basel 
www.karger.com/crg 
Zeitz et al.: New Onset, Aggravation and Recurrence of Crohn’s Disease upon 
Treatment with Three Different Tumor Necrosis Factor Inhibitors 
 
 
 
13 Van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince 
FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM: Development of inflammatory bowel disease in 
patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441–1446. 
14 Slebioda TJ, Kmiec Z: Tumour necrosis factor superfamily members in the pathogenesis of inflammatory 
bowel disease. Mediators Inflamm 2014;2014:325129. 
15 Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, 
Gomollón F, Hommes DW, Michetti P, O’Morain C, Oresland T, Windsor A, Stange EF, Travis SP; European 
Crohn’s and Colitis Organisation (ECCO): The second European evidence-based consensus on the diagnosis 
and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28–62. 
 
 
Fig. 1. Surgical specimen. a Macroscopic view. b Hematoxylin and eosin staining at 5-fold magnification 
revealing a fissure, transmural inflammation and architectural changes of the surrounding mucosa.  
c Hematoxylin and eosin staining at 100-fold magnification revealing non-caseating granulomas within a 
draining lymph node. 
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Fig. 2. a Overview of the clinical course. The time course of various pharmacological treatments and clini-
cal symptoms is indicated. The time points of the first (C1) and second (C2) colonoscopy and the time 
point of surgery are marked. b Serum levels of C-reactive protein (CRP). c Levels of stool calprotectin. 
 
